^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYN125

    i
    Associations
    News

    Trials

    Company:
    Synermore
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions (NCT04363242)
    Phase 1
    Synermore Biologics Co., Ltd.
    Active, not recruiting
    Last update posted :
    04/12/2023
    Initiation :
    04/09/2020
    Primary completion :
    07/31/2023
    Completion :
    09/30/2023
    EGFR
    |
    KRAS mutation • MSI-H/dMMR • EGFR expression
    |
    SYN004 • SYN125